This Title All WIREs
How to cite this WIREs title:
WIREs Syst Biol Med
Impact Factor: 4.192

Therapeutic genome engineering via CRISPR‐Cas systems

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Differences in genomes underlie most organismal diversity, and aberrations in genomes underlie many disease states. With the growing knowledge of the genetic and pathogenic basis of human disease, development of safe and efficient platforms for genome and epigenome engineering will transform our ability to therapeutically target human diseases and also potentially engineer disease resistance. In this regard, the recent advent of clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR‐associated (Cas) RNA‐guided nuclease systems have transformed our ability to target nucleic acids. Here we review therapeutic genome engineering applications with a specific focus on the CRISPR‐Cas toolsets. We summarize past and current work, and also outline key challenges and future directions. WIREs Syst Biol Med 2017, 9:e1380. doi: 10.1002/wsbm.1380 This article is categorized under: Laboratory Methods and Technologies > Genetic/Genomic Methods Translational, Genomic, and Systems Medicine > Therapeutic Methods
Schematic of in vivo and ex vivo gene therapy modalities. In vivo gene therapy involves the direct intra‐tissue or systemic injection of delivery agents, followed by assaying of targeting efficacy with close monitoring of safety and efficacy of treatment. In this regard, re‐administration of delivery agents might be necessary to achieve therapeutic efficacy. A patient might also be treated via ex vivo gene therapy, where patient somatic cells are isolated and either (1) reprogrammed into patient‐specific iPSCs, followed by gene therapy of these cells, and which are then differentiated into specific tissue types and cell lineages for transplantation; or (2) edited via ex vivo culture coupled with gene therapy (for instance in HSCs).
[ Normal View | Magnified View ]
The CRISPR‐Cas9 genome‐engineering toolset. (a) Wild‐type Cas9 induces double‐stranded DNA breaks, which the cell repairs through either nonhomologous end‐joining (NHEJ) or homologous recombination (HR) pathways. A mutated version of Cas9, ‘nickase’ Cas9, nCas9, is created by mutating one of the two catalytic sites, typically the RuvC domain, which results in engineering of only single stranded breaks. Modifications by Cas9 and nCas9 can used to also engineer genomic deletions or translocations. b) One can also utilize dead‐Cas9, dCas9, with both of its catalytic sites mutated, RuvC and HNH. dCas9 can in turn be tethered to effectors, such as activation or repression domains, to induce targeted genome regulation. In addition, other novel effectors can be utilized, such as fusion to the cytidine‐deaminase enzyme for targeted ‘base editing.’
[ Normal View | Magnified View ]

Related Articles

Aegean Conferences on Pathways, Networks, and Systems Medicine

Browse by Topic

Laboratory Methods and Technologies > Genetic/Genomic Methods
Translational, Genomic, and Systems Medicine > Therapeutic Methods

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts